诺瓦瓦克斯股票因FDA批准新型新冠疫苗而飙升25%

新浪财经
May 19

要点诺瓦瓦克斯(Novavax)的新型蛋白基新冠疫苗获得美国食品药品监督管理局(FDA)批准。这款名为 Nuvaxovid 的疫苗适用于老年人,以及 12 至 64 岁之间患有基础疾病、面临更高感染风险的人群。Nuvaxovid 由诺瓦瓦克斯与赛诺菲(Sanofi)合作开发,后者将根据里程碑协议向诺瓦瓦克斯支付 1.75 亿美元,未来还可能从疫苗销售中支付更多特许权使用费。美国食品药品监督管理局(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10